Our Vision Is To Be An Internationally Recognized Focal Point For Innovation, Creativity, Learning And Research Excellence Aligned With The Research Strengths Of Mcmaster University. Facilitates And Accelerates Innovation, The Transfer Of Knowledge And Th
Ultratech Has Gained The Reputation And Capabilities For Assisting Manufacturers And Designers In Obtaining The Appropriate Regulatory Product Compliance For Global Markets. Ultratechs Recognized Expertise Is In The Areas Of Product Modification And Re-De
CardioGenics is dedicated to develop more sensitive diagnostic test products to the IVD market. CardioGenics has started several developmental processes aimed to achieve its objective 'to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies'.CardioGenics' operating philosophy is that 'better diagnosis enhances the healthcare professionals' ability to provide better patient management which saves lives and reduces healthcare costs'. Fulfilling unmet clinical testing needs is the driving force behind CardioGenics' innovations.
CardioGenics is dedicated to develop more sensitive diagnostic test products to the IVD market. CardioGenics has started several developmental processes aimed to achieve its objective 'to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies'. operating philosophy is that 'better diagnosis enhances the healthcare professionals' ability to provide better patient management which saves lives and reduces healthcare costs'. Fulfilling unmet clinical testing needs is the driving force behind CardioGenics' innovations.
Often, pharmaceutical companies avoid new laboratory testing methodologies preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals. Furthermore, some pharmaceutical firms severely restrict academic research-based modifications to established laboratory testing procedures in drug development because of their concern over triggering costly adjustments to the established regulatory framework.